H1 2026 Korean Bio Investment Trends: The Oncology-Immunology Concentration
In the first half of 2026, venture capital invested in Korea's biohealth sector surpassed USD 9 billion, but the composition reveals a stark imbalance: more than USD 3.9 billion of that total flowed into oncology and immunology drug developers alone. The global frenzy around antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapy licensing deals has directly shaped domestic investor sentiment.
The problem is that this concentration has made fundraising markedly harder for biotech ventures working in non-oncology areas — metabolic disease, neurodegenerative disease, rare disease, and infectious disease pipelines. Startups increasingly face the question "do you have a plan to expand into oncology indications?" during investment rounds, and non-oncology pipelines are frequently valued lower than oncology assets at comparable clinical stages. As a result, for non-oncology biotech companies, a clear, persuasive IR narrative on "why invest in this pipeline now" has become just as critical as the underlying science.
Policy Shift: Venture Investment Fund Minimum Term Extended from 3 to 5 Years (Effective July 1, 2026)
Against this backdrop, an amended regulation took effect on July 1, 2026, extending the minimum duration of individual investment associations and venture investment associations from 3 years to 5 years. Since biotech drug development typically takes 3 to 5 years just to reach Phase 1 clinical entry, the previous 3-year fund structure created a structural mismatch — funds often faced exit pressure before clinical results were even available. The extension aligns fund lifecycles with biotech's actual development timeline, laying the groundwork for more patient capital to enter the sector.
Alongside this, new policy financing was introduced specifically for companies in the technology commercialization stage — the "Death Valley" gap between preclinical work and clinical entry. This is expected to serve as a critical bridge for biotech SMEs that secured early licensing deals or seed funding but are struggling to close follow-on rounds.
Practical Fundraising Strategies for Biotech SMEs
Given this environment, biotech SMEs have three concrete strategic options.
First, actively leverage public-private cooperation channels. Platforms such as the Biohealth Investment Council bring policy finance institutions and private VCs together in joint deal sourcing, placing greater weight on technical merit and public value in due diligence than purely private rounds do. In a market skewed toward oncology, these channels offer non-oncology pipelines a fairer path to evaluation.
Second, differentiate non-oncology pipelines through strategic positioning. Rather than relying on a single indication, presenting an indication-expansion roadmap and combination-therapy data that link back to oncology applications can significantly boost investor appeal. For example, a metabolic disease therapeutic that is backed by data on managing cancer treatment side effects or potential combination use with checkpoint inhibitors can broaden its investor base.
Third, strengthen the completeness of technology commercialization plans and IR materials. A hybrid fundraising strategy that connects government R&D funding with private investment requires materials that integrate not just the clinical development plan, but also government R&D project history, patent portfolio, and regulatory strategy.
KITIM supports biotech SMEs with advisory services for IR materials and technology commercialization plans, as well as fundraising strategies that connect government R&D projects with private investment. Companies seeking pipeline differentiation strategies and fundraising roadmaps amid the current oncology-focused investment climate are welcome to contact the KITIM consulting team.